Pharmaceutical intermediates have received much attention and favor from all walks of life. The Chinese government also attaches great importance to the development of pharmaceutical intermediates and has introduced a series of incentive policies and initiatives. Under the vigorous promotion of the government, China's pharmaceutical intermediate industry has developed rapidly. At present, it has basically met the chemical raw materials and intermediates required for pharmaceutical production.
According to the "China Pharmaceutical Intermediates Market Research and Investment Analysis Report" released by the Prospective Industry Research Institute, it is expected that with the expiration of the drug, the generic drug will usher in explosive growth with the price advantage in the next five to ten years, and production and sales are expected. Soaring. The outbreak of generic drugs will bring a broader market space and good development opportunities for pharmaceutical intermediates, and the future prospects are expected.
Pharmaceutical intermediates refer to some chemical raw materials or chemical products used in the process of drug synthesis, and are also an important part of fine chemicals. They have gradually become the core of the development of chemical industry in various countries. In recent years, China has made great progress in fine chemicals, and the refined rate has been continuously improved, creating a good atmosphere for the development of pharmaceutical intermediates.
Due to its high investment efficiency, high profit margin and high added value, pharmaceutical intermediates have attracted much attention and favor. The Chinese government also attaches great importance to the development of pharmaceutical intermediates and has introduced a series of incentive policies and initiatives.
Under the vigorous promotion of the government, China's pharmaceutical intermediate industry has developed rapidly. At present, it has basically met the chemical raw materials and intermediates required for pharmaceutical production, and presents the following six characteristics.
First, pharmaceutical intermediates are mostly private enterprises. The investment scale is generally small, and the investment amount is basically between several million and 120 million. However, the operation is more flexible and can respond quickly and effectively to market changes;
Second, the distribution of pharmaceutical intermediates is relatively concentrated, mainly in Jiangsu and Zhejiang, especially in Taizhou, Zhejiang and Jintan, Jiangsu, where a large number of pharmaceutical intermediates are gathered;
Third, pharmaceutical intermediates are facing increasing environmental pressures, and it is imperative to build environmental protection facilities;
Fourth, the product update is iterative, and new varieties emerge in an endless stream, forcing pharmaceutical intermediate companies to follow up or improve the process;
Fifth, the pharmaceutical intermediate industry is fiercely competitive and disorderly. More and more small and medium-sized chemical companies are joining, which is not conducive to the cluster development of the pharmaceutical intermediate industry;
Sixth, pharmaceutical intermediate enterprises generally lack innovation, and there are low-level duplication phenomena, and intermediate drugs with independent intellectual property rights in the world.
Judging from the above development characteristics, China's pharmaceutical intermediates are still far from the international advanced level. In the future, when promoting the development of the pharmaceutical intermediate industry, we must attach importance to scientific research investment, establish an engineering center with interdisciplinary, multi-faceted and high starting points as standards, provide a platform for the birth of new products, and carry out prediction and evaluation work to achieve rapid and healthy development of pharmaceutical intermediates. .
In general, pharmaceutical intermediates are expected to benefit as Chinese pharmaceutical companies develop generic drugs, but before that, problems such as overcapacity and vicious competition need to be addressed.
